SARS-CoV-2 hijacks neutralizing dimeric IgA for enhanced nasal infection and injury

Biao Zhou, Runhong Zhou, Jasper Fuk‐Woo Chan, Jianwei Zeng, Qi Zhang, Shuofeng Yuan, Li Liu, Rémy Robinot, Sisi Shan, Jiwan Ge, Hugo Yat-Hei Kwong, Dongyan Zhou, Haoran Xu, Chris Chung‐Sing Chan, Vincent Kwok‐Man Poon, Hin Chu, Ming Yue, Ka‐Yi Kwan, Chun-Yin Chan, Na Liu, Kenn Ka‐Heng Chik, Zhenglong Du, Ka‐Kit Au, Haode Huang, Hiu-On Man, Jianli Cao, Cun Li, Ziyi Wang, Jie Zhou, You‐Qiang Song, Man Lung Yeung, Kelvin Kai‐Wang To, David D. Ho, Lisa A. Chakrabarti, Xinquan Wang, Linqi Zhang, Kwok‐Yung Yuen, Zhiwei ChenbioRxiv 2021 · DOI

TL;DR

This study reveals a surprising mechanism by which SARS-CoV-2 exploits dimeric IgA (dIgA) antibodies, which are typically thought to be protective, to enhance its infection and cause more severe damage in the nasal passages. This finding challenges the conventional understanding of IgA's role in mucosal immunity against respiratory viruses and suggests new avenues for therapeutic strategies.

What Problem Does This Paper Address?

The high transmissibility of SARS-CoV-2, particularly through the upper respiratory tract, remains a critical challenge for pandemic control. While neutralizing antibodies, especially IgG, have been extensively studied for their therapeutic potential, the role of IgA, a key player in mucosal immunity, in controlling SARS-CoV-2 infection, especially in the nasal turbinate (NT), has been less clear. Specifically, it was unknown whether IgA antibodies could effectively neutralize the virus in the nasal cavity and prevent infection and subsequent damage. This paper investigates how different forms of IgA antibodies, engineered from a potent neutralizing IgG, behave in vivo against SARS-CoV-2 nasal challenge.

Methods

The researchers engineered a potent neutralizing IgG antibody (B8-IgG1) into various IgA forms: monomeric IgA1 (B8-mIgA1), monomeric IgA2 (B8-mIgA2), dimeric IgA1 (B8-dIgA1), and dimeric IgA2 (B8-dIgA2). They then evaluated these antibodies in a Syrian hamster model of intranasal SARS-CoV-2 infection. Key techniques included:

  • In vitro characterization: ELISA and pseudovirus neutralization assays were used to confirm the binding and neutralizing activities of the engineered IgA antibodies.
  • In vivo challenge studies: Hamsters were treated with the antibodies (prophylactically or therapeutically) and then challenged with live SARS-CoV-2. Viral loads were assessed using plaque assays (PFU) and RT-PCR for viral RNA. Tissue damage was evaluated through histological analysis and immunofluorescence staining for viral nucleocapsid protein (NP).
  • Mechanism investigation: To understand how dIgA might enhance infection, researchers investigated the role of CD209 (DC-SIGN) as an alternative entry receptor and performed cell-cell fusion assays.
  • Cryo-EM analysis: This technique was used to determine the structural basis of B8 antibody binding to the SARS-CoV-2 spike protein, revealing its binding mode and epitope.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Dimeric IgA's Unexpected Role: The most striking finding is that dimeric IgA antibodies (B8-dIgA1 and B8-dIgA2), while potent neutralizers in vitro, paradoxically enhanced SARS-CoV-2 infection and caused more severe damage in the nasal turbinate of hamsters, unlike monomeric IgA or IgG.
  • Hijacking CD209 for Entry: Virus-bound dIgA antibodies appear to engage CD209, a receptor found on cells that do not express ACE2 (the primary SARS-CoV-2 entry receptor), facilitating viral entry into these alternative cell types.
  • Facilitating Cell-to-Cell Transmission: This dIgA-mediated entry into CD209+ cells seems to promote viral spread, potentially through trans-infection mechanisms, leading to enhanced nasal infection and injury.
  • Structural Basis of Neutralization: Cryo-EM analysis revealed that the B8 antibody binds to the Receptor Binding Motif (RBM) of the SARS-CoV-2 spike protein in a manner consistent with Class II neutralizing antibodies, and this binding site overlaps with ACE2 binding.

Key Results

  • Intranasal administration of B8-dIgA1 or B8-dIgA2 led to an 81-fold increase in infectious viruses and more severe damage in the nasal turbinate compared to placebo.
  • While B8-IgG1 and monomeric IgA forms showed some suppression of viral load in the lungs, they were less effective in the nasal turbinate.
  • Dimeric IgA antibodies (B8-dIgA1 and B8-dIgA2) were found to enhance SARS-CoV-2 infection in cells expressing CD209 but not ACE2.
  • Cryo-EM structures showed that B8 binds to the SARS-CoV-2 spike protein in both "3-up" and "2-up/1-down" RBD conformations.

Limitations and Future Work

  • Hamster Model: The findings are based on a Syrian hamster model, and it remains to be determined if similar mechanisms occur in humans. The authors suggest further studies are needed to investigate CD209+ DC recruitment in human nasal mucosa during SARS-CoV-2 infection.
  • NTD-specific IgA: The study did not include NTD-specific neutralizing IgA for comparison.
  • Other Receptors: The role of other cellular receptors, such as the polymeric immunoglobulin receptor (pIgR), in dIgA-enhanced infection was not explored.
  • Vaccine/Treatment Implications: It is unknown whether dIgA-mediated enhancement could occur in individuals vaccinated or treated with IgA, and future studies are needed to address this.
  • Future Directions: The authors suggest investigating other classes of neutralizing IgA and exploring the role of pIgR. They also highlight the need for future studies to address the limitations mentioned above, particularly regarding human relevance and potential implications for vaccination and therapeutic interventions.

Summary updated

Abstract

ABSTRACT Robust severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in nasal turbinate (NT) accounts for high viral transmissibility, yet whether neutralizing IgA antibodies can control it remains unknown. Here, we evaluated receptor binding domain (RBD)-specific monomeric B8-mIgA1 and B8-mIgA2, and dimeric B8-dIgA1 and B8-dIgA2 against intranasal SARS-CoV-2 challenge in Syrian hamsters. These antibodies exhibited comparably potent neutralization against authentic virus by competing with human angiotensin converting enzyme-2 (ACE2) receptor for RBD binding. While reducing viruses in lungs, pre-exposure intranasal B8-dIgA1 or B8-dIgA2 led to 81-fold more infectious viruses and severer damage in NT than placebo. Virus-bound B8-dIgA1 and B8-dIgA2 could engage CD209 as an alternative receptor for entry into ACE2-negative cells and allowed viral cell-to-cell transmission. Cryo-EM revealed B8 as a class II neutralizing antibody binding trimeric RBDs in 3-up or 2-up/1-down conformation. Therefore, RBD-specific neutralizing dIgA engages an unexpected action for enhanced SARS-CoV-2 nasal infection and injury in Syrian hamsters.
BibTeX
@misc{zhou2021sars,
  author = {Biao Zhou and Runhong Zhou and Jasper Fuk‐Woo Chan and Jianwei Zeng and Qi Zhang and Shuofeng Yuan and Li Liu and Rémy Robinot and Sisi Shan and Jiwan Ge and Hugo Yat-Hei Kwong and Dongyan Zhou and Haoran Xu and Chris Chung‐Sing Chan and Vincent Kwok‐Man Poon and Hin Chu and Ming Yue and Ka‐Yi Kwan and Chun-Yin Chan and Na Liu and Chris Chun-Yiu Chan and Kenn Ka‐Heng Chik and Zhenglong Du and Ka‐Kit Au and Haode Huang and Hiu-On Man and Jianli Cao and Cun Li and Ziyi Wang and Jie Zhou and You‐Qiang Song and Man Lung Yeung and Kelvin Kai‐Wang To and David D. Ho and Lisa A. Chakrabarti and Xinquan Wang and Linqi Zhang and Kwok‐Yung Yuen and Zhiwei Chen},
  title = {{SARS-CoV-2 hijacks neutralizing dimeric IgA for enhanced nasal infection and injury}},
  year = {2021},
  doi = {10.1101/2021.10.05.463282},
  howpublished = {bioRxiv},
}
Figure